With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Oxford BioTherapeutics (OBT) has lined up another big pharma partner for its drug discovery platform, agreeing to work with ...

A research led by Sergio P. Acebrón, Researcher Ikerbasque at the UPV/EHU, develops a key tool to visualize the immune response to abnormal DNA, opening new avenues for the treatment of diseases.

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...

Veeva Systems (NYSE: VEEV) today announced that Indero, formerly Innovaderm Research, successfully launched its 40th RTSM study on Veeva ...

Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...

With symptoms that often mimic other respiratory conditions, ILD is frequently misdiagnosed or unrecognized. However, in the Philippines, hope is in the horizon.

One company decreased its PED outbreaks by about 90% by starting to wash market trailers, said Dr. Meghann Pierdon, a ...

A team at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) led by Dr. Andrés Hidalgo has discovered a specialized population of ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Significant alterations in the structure and cellular composition of the distal lung are a defining characteristic of ...

In March 2025, Vertex Pharmaceuticals Incorporated announced a study is to evaluate the safety, and tolerability and efficacy ...